News Oligomerix Awarded $2.18 Million SBIR Grant for Tau Oligomer Inhibitor for Alzheimer’s Disease and Related Disorders October 10, 2019 By vera This article is sourced from an external publication. Read the original → ← PreviousOligomerix Receives Ongoing Support from NIH and Moves Forward with IND-enabling StudiesNext →Oligomerix and Feinstein Institutes Publish In Vivo Alzheimer’s Disease Treatment Data
